ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid

The Benefits of Blood Money: OxyContin & Ethics

Philip Seo, MD, MHS  |  March 18, 2019

On Feb. 9, 2019, protesters gathered at the Guggenheim Museum in New York City to lead a march down Fifth Avenue to the Metropolitan Museum of Art.1 As a general rule, news from the world of art is not a topic discussed in these pages, but if you indulge me for just a little bit…

Filed under:EthicsOpinionRheuminationsSpeak Out Rheum Tagged with:Arthur M. Sackler FoundationDr. Mortimer and Theresa Sackler Foundationopioid crisisopioid use disordersOxyContinPurdue PharmaRaymond and Beverly Sackler Foundation

U.S. FDA Chief Gottlieb Resigns

Yasmeen Abutaleb  |  March 5, 2019

WASHINGTON (Reuters)—U.S. Food and Drug Administration (FDA) Chief Scott Gottlieb said he plans to step down in a month, calling into question how the agency will handle critical issues, such as e-cigarette use among teens and efforts to increase competition in prescription drugs. The U.S. Department of Health and Human Services (HHS), which oversees the…

Filed under:Professional Topics Tagged with:FDAFDA Commissioner Scott GottliebFood and Drug AdministrationU.S. Food and Drug Administration (FDA)

Tanezumab for OA Pain

Michele B. Kaufman, PharmD, BCGP  |  February 21, 2019

In a recent study, tanezumab proved more effective than placebo in treating patients with moderate to severe pain caused by hip or knee osteoarthritis…

Filed under:AnalgesicsDrug Updates

Ibuprofen an Option for Early Pain Control after Hip Replacement

Reuters Staff  |  February 13, 2019

NEW YORK (Reuters Health)—Combining paracetamol (acetaminophen) with ibuprofen does not cut postoperative use of morphine in a clinically meaningful way relative to ibuprofen alone, in patients undergoing total hip arthroplasty (THA), results of a Danish randomized trial suggest. “Although the combined use of paracetamol and ibuprofen reduced immediate postoperative morphine consumption compared with paracetamol alone…

Filed under:AnalgesicsDrug Updates Tagged with:hiphip arthroplastyIbuprofenPainPain Managementsurgerytotal hip arthroplastytotal hip replacement

Update & Changes to the OIG Work Plan

From the College  |  February 8, 2019

Early last fall, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) released its OIG Work Plan for fiscal year 2018–2019, which is a two-year framework for the audits, inspections, evaluations and investigative activities planned in support of its vision, mission, and strategic goals and objectives to maintain HHS program integrity….

Filed under:From the CollegePractice Support Tagged with:evaluation and management (E/M)HHS programMedicare AdvantageMedicare paymentsOffice of Inspector General (OIG)OIG Work PlanOpioid misuse

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2019

Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…

Filed under:AnalgesicsDrug Updates Tagged with:Biologics & BiosimilarsBiosimilarsCanadaetanerceptFDAgeneric drug marketnaloxoneopioidOpioid abusepsoriatic arthritisU.S. Food and Drug Administration (FDA)

OA Patient-Reported Outcomes Positive for Intra-Articular Injection

Carina Stanton  |  January 21, 2019

In a recent Phase 2 clinical trial, patient-perceived pain and function measures improved with SM04690, an injectable, disease-modifying osteoarthritis treatment currently in development…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:intra-articular Wnt-β catenin inhibitorjoint injectionkneeknee osteoarthritisKnee Osteoarthritis (OA)SM04690

The Eliminating Kickbacks in Recovery Act of 2018—What Does It Mean?

Steven M. Harris, Esq.  |  January 17, 2019

It should not be a surprise to anyone that the U.S. is facing a national opioid crisis. It may be a surprise, however, that the federal government recently passed a law to address this crisis—a law that may have a profound impact on many healthcare facilities, some of which are not involved in the substance…

Filed under:Drug UpdatesLegal Updates Tagged with:opioid crisissubstance abuse

Patients with Prediabetes May Be Predisposed to Arthritis

Lara C. Pullen, PhD  |  January 2, 2019

New research from the CDC shows that approximately one-third of U.S. adults with prediabetes also have arthritis, which can prevent physical activity in these patients, thereby, making it more likely they will develop type 2 diabetes…

Filed under:Conditions

ACR Leaders Discuss E/M Coding Changes, Step Therapy & More

Thomas R. Collins  |  December 18, 2018

CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…

Filed under:Billing/CodingLegislation & AdvocacyMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingBiosimilarsE/M CodingH1B visasstep therapy

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences